Short-term outcomes of down-referral in provision of paediatric antiretroviral therapy at Red Cross War Memorial Children’s Hospital, Cape Town, South Africa: A retrospective cohort study by Copelyn, J et al.
432       May 2018, Vol. 108, No. 5
RESEARCH
The HIV/AIDS epidemic has had a dramatic impact on the 
health of South Africa (SA)’s children, contributing substantial 
morbidity and mortality. Without antiretroviral therapy (ART) 
it is estimated that >50% of perinatally infected children will 
die before their second birthday,[1] primarily as a result of rapid 
disease progression, early severe HIV disease or life-threatening 
co-infections.[2] The SA national ART programme was launched in 
April 2004 and is now the biggest programme in the world, with 
>3 million people receiving ART, including an estimated 160 000 
children. Since its inception, the national ART programme has 
grown rapidly and resulted in substantial positive change. Through 
improvements in the prevention of mother-to-child transmission 
(PMTCT) programme, vertical transmission was reduced from 
15% in 2009 to 4% in 2014, averting an estimated 370 000 new 
childhood HIV infections.[3] The 2013 national guideline[4] further 
expanded paediatric access to ART by broadening initiation 
criteria to include all HIV-infected children aged <5 years. By 
2014, almost half of all HIV-infected children in the country were 
accessing ART. While still significantly below target, this was an 
increase from just 11% in 2009.[3]
In the push for rapid scale-up of ART provision and improvement in 
ART coverage, the SA government adopted a public health approach to 
HIV care. Central to this approach are the two closely linked concepts 
of task shifting and decentralisation. Task shifting entails ‘lower’ 
cadres of healthcare providers, and sometimes non-professionals, 
taking over responsibilities previously held by doctors or ‘higher’ 
cadres of healthcare workers.[5] Decentralising care includes moving 
care from tertiary referral centres to healthcare centres or clinics, and 
even beyond clinics into communities, closer to patients’ places of 
residence.[6] For many patients this has required a process of down-
referral to sites with less specialised healthcare facilities. Progress with 
paediatric down-referral has been slow, however, in part owing to 
healthcare worker perceptions regarding the complexity of managing 
HIV-infected children.
The paediatric ART programme in the Western Cape Province, SA, 
has made considerable efforts to decentralise care of HIV-infected 
children. Between March 2004 and December 2015, the number of 
clinics in the province treating children with ART increased from 
11 to 180, and the percentage of children receiving ART from the 
three Cape Town tertiary hospitals declined from 78.4% to 14.7%[7] 
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Background. The large scale-up of paediatric HIV care necessitated down-referral of many children receiving antiretroviral therapy (ART) 
from Red Cross War Memorial Children’s Hospital (RCWMCH), Cape Town, South Africa. Few published data exist on the outcomes of these 
children.
Objectives. To assess outcomes of children receiving ART in the first 12 months after down-referral to primary healthcare (PHC) clinics and 
identify determinants of successful down-referral.
Methods. A retrospective cohort study of children <15 years of age who initiated ART at RCWMCH and were subsequently down-referred to 
one of two PHC clinics between January 2006 and December 2012 was completed. Baseline characteristics of patients and caregivers as well 
as CD4+ counts, viral loads (VLs) and weights were collected 6 and 12 months after down-referral. Outcomes included retention in care and 
viral suppression.
Results. Of 116 children down-referred to the two study PHC clinics, 81.9% arrived at the designated PHC clinic and a further 8.6% continued 
care at other clinics, the remaining 9.5% being lost to follow-up. Of those successfully down-referred, 11.4% took >8 weeks to present, possibly 
experiencing treatment interruption. At 12 months after down-referral, only 81.0% remained in care. No factors were associated with retention 
in care in multivariable analysis. For children who remained in care at the designated PHC clinics, the clinical and immunological gains 
achieved prior to down-referral were sustained through 12 months of follow-up, and 54.7% of this cohort had documented viral suppression 
at 12 months. However, if only children with VL results are considered, 75.9% (41/54) were virally suppressed 12 months after down-referral.
Conclusions. Down-referral of children on ART is complex, with risk of loss to follow-up and treatment interruption.
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(and ART Monthly Enrolment Summaries, 2015, HAST (HIV & 
AIDS, STI and TB) Directorate, Department of Health Western 
Cape – unpublished data). By 2007/2008 the ART coverage rate in 
the province had improved to >95%, well exceeding the national 
average of 37%.[8] This was a consequence of both significant gains 
in PMTCT of HIV and expansion of the paediatric ART programme 
into primary healthcare (PHC) settings. This decentralised model of 
care necessitated down-referral of large numbers of children from 
tertiary academic hospitals to community-based clinics. Data on both 
the success of the down-referral process and the clinical outcomes of 
these children after down-referral are severely limited. In a recent 
study of transfer in adolescents receiving ART in the Western Cape, 
>80% transferred successfully from tertiary care facilities to PHC 
clinics.[9] In a further study of younger children receiving ART at 
physician-run PHC clinics, almost all of 270 children who had 
been down-referred from tertiary care in the Western Cape either 
sustained or achieved virological suppression over a median of 28 
months of follow-up.[10]
Objective
To assess the success of the down-referral process and the clinical 
and ART outcomes in a cohort of young children, and to explore 
determinants of successful down-referral.
Methods
Setting
The study was conducted at Red Cross War Memorial Children’s 
Hospital (RCWMCH) and two PHC clinics in Cape Town.
RCWMCH is a tertiary facility that serves as a referral centre for the 
paediatric population of the Western Cape and surrounding provinces. 
HIV-infected children have been accessing ART through this service 
since 1998. Since 2006, in accordance with the provincial framework 
for managing HIV-infected children, many children have been actively 
down-referred, mainly to level 1 paediatric HIV clinics in the Cape 
metropolitan area. Down-referral criteria have not been standardised, 
and while clinicians in the outpatient HIV clinic (OHC) are encouraged 
to down-refer stable patients with clinical and laboratory evidence of 
compliance and immune recovery (such as no opportunistic infections, 
suppressed viral load (VL) and recovering CD4+ count), decisions are 
made on an individual patient basis. Furthermore, as the provincial 
ART programme matured, down-referral of children initiated on ART 
during hospital admission began to occur at discharge from inpatient 
care. Down-referral is facilitated by clinicians telephonically arranging 
the first PHC clinic appointment and providing caregivers with a 
written clinical summary for clinic staff.
The two PHC study clinics fall within the immediate drainage area 
of RCWMCH and are <10 km apart. One is a large, well-established 
clinic that has been providing a paediatric HIV service since 2003. 
In comparison, the other is a much smaller clinic, which only began 
its paediatric ART outpatient service in 2010. Both paediatric HIV 
clinics are medical officer led.
Study design
The hospital ART database was used to identify all children who 
initiated ART at RCWMCH and were subsequently down-referred 
to either of the two PHC clinics between 1 January 2006 and 31 
December 2012.
Baseline characteristics of patients and their caregivers were 
retrospectively extracted from case record forms held by the 
infectious diseases clinic. Hospital folders were further reviewed to 
extract information relating to hospital admission diagnoses, length 
of follow-up at RCWMH and clinical and virological parameters 
prior to the point of down-referral. CD4+ percentage (CD4%) and 
VLs prior to down-referral were accepted within a window period 
of 6 months.
At the PHC clinics, data were again retrospectively collected 
from patient folders, including the time between down-referral 
(last appointment at RCWMCH) and presentation at the PHC and 
outcomes at 6 and 12 months after down-referral. Measures included 
the patient’s weight and CD4% and VL results. For 6- and 12-month 
CD4% and VL results, the closest measures within a window period 
of 4 - 8 and 9 - 15 months, respectively, were used.
For patients whose outcomes could not be established at the two 
designated PHC clinics, the Western Cape Provincial Health Data 
Centre (PHDC) searched available provincial electronic databases for 
data on clinic visits, HIV-related laboratory tests and antiretroviral 
drugs dispensed for these children during the 12-month period after 
down-referral. The PHDC collates information on individual patients 
using a unique health identifier (folder number) across multiple 
patient information systems in the province.
Anthropometric measurements such as weight and height were 
converted to gender-specific weight-for-age z-scores (WAZ), height-
for-age z-scores (HAZ) and weight-for-height z-scores (WHZ) scores, 
according to the 2000 Centers for Disease Control and Prevention 
(CDC) growth charts.[11] CDC charts were used because they covered 
the full age range of patients in the study cohort. Moderate under-
weight for age, stunting and wasting were defined as WAZ, HAZ 
and WHZ between –2 and –3 z-scores, <–3 being defined as severe 
underweight, stunting and wasting. Specific outcomes measured at 
6 and 12 months after down-referral included mean WAZ, WAZ 
category, median CD4%, the proportion of children with severe 
immunodeficiency as defined by the World Health Organization 
(WHO),[12] the proportion who were virologically suppressed (defined 
as a VL <400 copies/mL), and at 12 months the proportions who 
remained in care or had been lost to follow-up (LTFU).
Data analysis
Data were collected on a standardised data capture sheet and inputted 
into Excel version 14.7.1 (Microsoft, USA). Data were analysed using 
Stata software (Stata/IC 13.0 for Windows, StataCorp USA). Means 
and standard deviations (SDs) or medians and interquartile ranges 
(IQRs) were used to describe normally and non-normally distributed 
data, respectively. Student’s t-test was used to compare normally 
distributed data and the Wilcoxon sum-rank test was used for skewed 
data. Categorical data were compared using the χ2 test or Fisher’s 
exact test, as appropriate.
Univariate analyses using the unadjusted risk ratio (RR) and 
95% confidence intervals (CIs) as well as multivariable logistic 
regression modelling were performed to identify potential factors 
associated with retention in care at PHC clinics 12 months after 
down-referral.
Ethics considerations
The study was approved by the Human Research Ethics Committee, 
Faculty of Health Sciences, University of Cape Town (ref. no. 
246/2013) and the Western Cape Department of Health. Patient 
consent was not obtained because the data were collected and 
collated retrospectively. The study was completed in accordance with 
the Declaration of Helsinki.
Results
The hospital ART database search identified 119 children meeting 
the study inclusion criteria. On further examination, 3 children 
were excluded from the analysis; 1 had initiated ART prior to 
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presentation at RCWMCH, and 2 were 
not actively down-referred but rather ‘self-
down-referred’ without the knowledge of 
attending clinicians. Data for the remaining 
116 children, referred to as the study cohort, 
were analysed (Fig. 1).
Baseline characteristics
The majority of the study cohort (61.2%) was 
female. The median age at ART initiation was 
11 months, and 52.6% were <12 months of 
age. Moderate or severe wasting and stunt-
ing were present in 29.2% and 39.3% of 
participants, respectively. There were no sta-
tistically significant differences in baseline 
sociodemographic or anthropometric fea-
tures between participants who were and 
those who were not retained in care (RIC) at 
12 months after down-referral (Table 1).
The mother was the primary caregiver for the 
majority of participants (87.1%). However, 
very few mothers (14.4%) were taking ART 
themselves and only 38.7% had received 
any PMTCT prophylaxis. Compared with 
participants who were RIC, a greater pro-
portion of those not RIC after down-referral 
were receiving support grants at ART 
initiation (80.0% v. 50.0%, respectively.)
HIV diagnosis and hospitalisation
The majority of the study cohort (79/116, 
68.1%) had undiagnosed HIV infection 
prior to referral to RCWMCH. Only 
19.8% were diagnosed at a PHC clinic, 
the remainder having been diagnosed at 
other hospitals or by private doctors. At the 
time of ART initiation, 90.2% of the study 
cohort had advanced clinical disease (WHO 
clinical stage 3 or 4), and the median (IQR) 
CD4% was 18% (11 - 23). Treatment for 
coexistent tuberculosis (TB) was required 
by 18.1% of the study cohort, 23.8% (5/21) 
of whom were treated for extrapulmonary 
TB (Table 2).
Not all the children required hospitalisa-
tion; 13.9% were managed exclusively on 
an outpatient basis at the OHC. For the 99 
children who were admitted to hospital, 
the mean (SD) length of stay was 19 (14) 
days and the most common admission diag-
noses were acute lower respiratory tract 
infection (52.5%) and diarrhoeal disease 
(36.4%). Most of the children were managed 
in general medical or acute short-stay wards 
(70.2%). However, 15.8% required admis-
sion to the intensive care unit. ART initiation 
occurred in an inpatient setting for 61.7% of 
the cohort, while the remaining 38.3% initi-
ated ART in the OHC.
ART management prior to  
down-referral
All children in the study cohort were 
initiated on ART at RCWMCH. While 
the median number of days between HIV 
diagnosis and ART initiation was 42, this 
declined progressively from 414 days for 
those diagnosed before 2005 to 15 days for 
those diagnosed in 2011/2012, a decrease 
of 96%.
Of the children who required hospitali-
sation, 21.2% (21/99) were initiated on 
ART and down-referred to PHC clinics 
to continue their treatment at the time 
of discharge. The remaining 95 children 
who were seen at the OHC at RCWMCH 
were followed up for a median of 320 days 
(IQR 189 - 685), with a mean (SD) number 
of 12 (8) clinic visits prior to down-referral, 
and 26.6% (25/94) of these children had 
at least one hospital admission during 
follow-up. The median age at down-referral 
was 26 months (IQR 12 - 52). At down-
referral, 47.4% (55/116) of the cohort had 
a documented suppressed VL within the 
preceding 6 months. In a further 12.1% 
(14/116) no VL was done prior to down-
referral, and in the remaining 40.6% 
(47/116) the last VL prior to down-referral 
was unsuppressed. Five children who 
had defaulted from ART while attending 
RCWMCH were down-referred to restart 
therapy at the referral clinic.
Outcomes after down-referral
Once down-referred, 90.6% (105/116) of 
children presented for treatment continu-
ation, 81.9% (95/116) at the designated PHC 
clinic and a further 8.6% (10/116) at other 
Children who initiated ART at RCWMCH between 
1 January 2006 and 31 December 2012 from study area 
N=231
Not down-referred
n=112
Excluded from analysis
n=3 (n=1 started ART before transfer to RCWMCH, 
n=2 LTFU not actively down-referred)
Down-referred from RCWMCH to two 
designated PHC clinics
n=116
LTFU at point of down-referral
n=11
Arrived at any PHC clinic in Western Cape for 
treatment continuation
n=105 (n=95 at the designated PHC clinics, 
n=10 at other treatment facilities)
Died
n=1
 Remained in care in Western Cape 12 months 
after down-referral
n=94 (n=75 at the designated PHC clinics, 
n=19 at other clinics)
LTFU
n=10
Fig. 1. Selection of study subjects and their progression during the study period. (ART = antiretroviral 
therapy; RCWMCH = Red Cross War Memorial Children’s Hospital; LTFU = lost to follow-up; PHC = 
primary healthcare.)
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PHC clinics or hospitals. The median time between down-referral 
and presentation was 27 days (IQR 19 - 33). However, 11.4% (12/105) 
presented >8 weeks after down-referral, with a median of 77 days 
(IQR 66 - 129) days between down-referral and presentation. At the 
point of down-referral, 19.8% of patients were either LTFU (11/116) 
or experienced possible treatment interruption (12/116).
Twelve months after down-referral, 81.0% (94/116) of the study 
cohort remained in care, 64.7% (75/116) at the designated PHC clinic 
and a further 16.4% (19/116) at other sites. One patient had died. The 
remaining 18.1% (21/116) were LTFU, 52.4% (11/21) at the point of 
down-referral, having not attended a single PHC clinic visit in the 
Western Cape. Of those LTFU, 42.9% (9/21) were <12 months of age 
at the time of ART initiation.
Response to ART at designated down-referral clinics
The 75 children who remained in care at the designated down-referral 
clinics showed sustained clinical and immunological response to 
ART over the 12 months of follow-up (Table 3).
The proportion of children with moderate to severe underweight 
for age declined steadily from 50.7% (38/75) at initiation to 8.0% 
(6/75) 12 months after down-referral (p<0.001). The median 
CD4% had increased from 17% (IQR 11 - 23) at initiation to 31% 
(IQR 23 - 37) at down-referral (p<0.001), and this was sustained 
over 12 months of follow-up in the PHC clinics. The percentage 
of children with severe immunodeficiency declined from 69.3% 
at initiation to 1.3% 12 months after down-referral (p<0.001). 
Similar rates of viral suppression were documented at down-
referral (50.7%, 38/75) and 12 months after down-referral (54.7%, 
41/75) (p=0.62). However, if only those children with documented 
VLs are considered, rates of viral suppression were much higher 
both at down-referral (86.4%, 38/44) and 12 months later (75.9%, 
41/54).
Despite these markers of improvement, 14.7% (11/75) required at 
least one hospital admission during the first year of follow-up after 
down-referral.
Predictors of retention in care 12 months after  
down-referral
In univariate analysis, TB coinfection at the time of ART initi-
ation was significantly less prevalent in children RIC at 12 months 
Table 1. Baseline characteristics at ART initiation
  Total (N=116)* Not RIC (n=22)* RIC (n=94) p-value†
Sociodemographics  
Male sex, n (%) 45 (38.8) 8 (36.4) 37 (39.4) 0.795
Age at initiation, median (IQR) 11 (4 - 38) 18 (6 - 41) 8 (4 - 37) 0.302‡
Age group (years), n (%) 0.266
<1 61 (52.6) 9 (40.9) 52 (55.3)
1 - 5 36 (31.0) 10 (45.5) 26 (27.7)
>5 19 (16.4) 3 (13.6) 16 (17.0)
Anthropometry 
WAZ, mean (SD) –2 (2) –2 (2) –2 (2) 0.432
WAZ categories, n (%) 0.513
Mild-normal 55 (47.4) 8 (36.4) 47 (50.0)
Moderate underweight 31 (26.7) 7 (31.8) 24 (25.5)
Severe underweight 30 (25.9) 7 (31.8) 23 (24.5)
HAZ, mean (SD) –2 (2) –2 (2) –2 (1) 0.364
HAZ categories, n (%) 0.587
Mild-normal 65 (60.7) 11 (55.0) 54 (62.1)
Moderate stunting 23 (21.5) 6 (30.0) 17 (19.5)
Severe stunting 19 (17.8) 3 (15.0) 16 (18.4)
WHZ, mean (SD) –1 (2) –1 (2) –1 (2) 0.926
WHZ categories, n (%) 0.428
Mild-normal 75 (70.8) 12 (60.0) 63 (73.3)
Moderate wasting 17 (16.0) 5 (25.0) 12 (14.0)
Severe wasting 14 (13.2) 3 (15.0) 11 (12.8)
Social/family, n (%) 
Mother alive 109 (94.0) 22 (100.0) 87 (92.6) 0.187
Mother primary caregiver 101 (87.1) 20 (90.9) 81 (86.2) 0.551
Mother on ART 15/104 (14.4) 3/21 (14.3) 12/83 (14.5) 0.984
Any maternal PMTCT prophylaxis 41 (38.7) 7 (31.8) 34 (40.5) 0.458
Literate primary caregiver 77/81 (95.1) 9/11 (81.8) 68/70 (97.1) 0.087§
Formal housing 62 (53.9) 9 (42.9) 53 (56.4) 0.261
Household treatment support 67/98 (68.4) 11/16 (68.8) 56/82 (68.3) 0.971
Accessing support grant 61 (55.5) 16 (80.0) 45 (50.0) 0.015
ART = antiretroviral therapy; RIC = retained in care; IQR = interquartile range; SD = standard deviation; WAZ = weight-for-age z-scores; HAZ = height-for-age z-scores;  
PMTCT = prevention of mother-to-child transmission.
*If >10% of the values were missing data, the total is reported in the column.
†p-value comparing participants RIC at 12 months after down-referral with those not retained in care.
‡Wilcoxon rank-sum test.
§Fisher’s exact test.
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after down-referral than those not RIC (13.8% v. 33.3%, RR 0.4, 
95% CI  0.2  - 0.9), and the proportion of caregivers in receipt of a 
social grant at the time of ART initiation was significantly lower for 
children RIC at 12 months of ART than for those not RIC (51.1% v. 
78.9%, RR 0.7, 95% CI 0.5 - 0.9). However, in multivariable logistic 
regression modelling, neither factor retained significance.
Table 2. Clinical, disease and management factors at ART initiation
  Total (N=116) Not RIC (n=22) RIC (n=94) p-value*
Disease factors
WHO clinical stage, n (%) 0.977
1 4 (3.6) 1 (5.0) 3 (3.3)
2 7 (6.3) 1 (5.0) 6 (6.5)
3 50 (44.6) 9 (45.0) 41 (44.6)
4 51 (45.5) 9 (45.0) 42 (45.7)
CD4+ absolute count (cells/µL), median (IQR) 585 (249 - 1 067) 665 (276 - 1 149) 561 (249 - 1 056) 0.584
CD4%, median (IQR) 18 (11 - 23) 19 (16 - 24) 17 (11 - 23) 0.251
Log10 VL (copies/mL), median (IQR) 6 (5 - 6) 5 (5 - 6) 6 (5 - 6) 0.196
Severe immunodeficiency†, n (%) 79 (68.7) 13 (59.1) 66 (71.0) 0.280
Clinical factors, n (%)
Up-to-date immunisation status 86/100 (86.0) 14/18 (77.8) 72/82 (87.8) 0.267
TB treatment at initiation 21 (18.1) 7 (31.8) 14 (14.9) 0.048
Clinical management factors
Highest level of care at RCWMCH, n (%) 0.726
Ward 80 (70.2) 16 (76.2) 64 (68.8)
ICU 18 (15.8) 3 (14.3) 15 (16.1)
OHC 16 (14.0) 2 (9.5) 14 (15.1)
Place of ART initiation, n (%) 0.970
Ward 60 (52.2) 12 (54.6) 48 (51.6)
ICU 11 (9.6) 2 (9.1) 9 (9.7)
OHC 44 (38.3) 8 (36.4) 36 (38.7)
Time from HIV diagnosis to ART initiation, median (IQR) 42 (14 - 184) 28 (13 - 154) 42 (14 - 199) 0.805
Follow-up at RCWMCH >6 months, n (%) 74 (63.8) 11 (50.0) 63 (67.0) 0.135
Suppressed VL prior to down-referral‡, n (%) 55 (47.4) 7 (31.8) 48 (51.1) 0.104
ART = antiretroviral therapy; RIC = retained in care; IQR = interquartile range; CD4% = CD4+ percentage; VL = viral load; TB = tuberculosis; RCWMCH = Red Cross War Memorial Children’s 
Hospital; ICU = intensive care unit; OHC = outpatient HIV clinic.
*p-value comparing participants RIC at 12 months after down-referral with those not retained in care.
†Severe immunodeficiency as defined by WHO age and CD4% cut-off criteria.
‡Suppressed VL within 6 months of down-referral compared with either not tested or not suppressed.
Table 3. Longitudinal changes of the 75 children who remained in care at the designated down-referral clinics 12 months after 
down-referral
  Initiation At down-referral
6 months after down-
referral
12 months after down-
referral
WAZ, mean (SD) –2 (2) –1 (1) 0 (1) 0 (1)
WAZ categories, n (%)  
Mild-normal 37 (49.3) 54 (72.0) 66 (88.0) 65 (86.7)
Moderate 19 (25.3) 5 (6.7) 4 (5.3) 5 (6.7)
Severe 19 (25.3) 3 (4.0) 1 (1.3) 1 (1.3)
Unknown 0 (0.0) 13 (17.3) 4 (5.3) 4 (5.3)
CD4%
Children, n 75 45 54 45
Median (IQR) 17 (11 - 23) 31 (23 - 37) 33 (26 - 39) 32 (27 - 35)
Severe immunodeficiency*, n (%)
Yes 52 (69.3) 4 (5.3) 6 (8.0) 1 (1.3)
No 23 (30.7) 41 (54.7) 48 (64.0) 49 (65.3)
Unknown 0 (0.0) 30 (40.0) 21 (28.0) 25 (33.3)
Suppressed VL, n (%)
Yes 0 (0.0) 38 (50.7) 47 (62.7) 41 (54.7)
No 67 (89.3) 6 (8.0) 13 (17.3) 13 (17.3)
Unknown/not done 8 (10.7) 31 (41.3) 15 (20.0) 21 (28.0)
WAZ = weight-for-age z-scores; SD = standard deviation; CD4% = CD4+ percentage; IQR = interquartile range; VL = viral load; WHO = World Health Organization.
*Defined by WHO age and CD4% cut-off criteria.
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Discussion
The present study showed that for children who remained in care 
at the designated PHC clinics, clinical and immunological gains 
achieved on ART were sustained for at least 12 months after down-
referral. The results were consistent with those from larger studies in 
similar cohorts.[13,14] It has also shown important negative outcomes 
associated with the down-referral process, with 18.9% of the study 
cohort LTFU, 50.0% of whom never presented to PHC clinics, 
and a further 11.4% having >8 weeks between down-referral and 
presentation to PHC clinics.
Similar patterns of LTFU and treatment interruptions were repor-
ted in a recent study from Dora Nginza Hospital in Port Elizabeth, 
Eastern Cape Province. In that study, of 644 children receiving ART 
who were transferred to primary and community health clinics for 
continuation of care, 33% never arrived at the designated clinic after 
down-referral. [15] Furthermore, among the 1 582 children initiated on 
ART during the study period, 53% of all loss to follow-up occurred 
through unsuccessful down-referral. Finally, by searching the National 
Health Laboratory Service database, results for 62% (131/211) of 
those lost to follow-up on down-referral were obtained, and only 
5% (10/211) of them were within 18 months of down-referral. This 
suggests that while many children did re-engage in care, significant 
treatment interruptions were common.
Both these SA studies are in stark contrast to a study conducted 
in Thailand, in which of 168 children down-referred from a tertiary 
hospital to several community hospitals, none were LTFU during a 
median follow-up time of 18 months.[16] This perfect retention in care 
can be attributed to the intensive support and adherence counselling 
provided after down-referral, with ongoing involvement of the referral 
team, who provided active mentorship and clinical support to the 
treating teams in the community hospitals as well as 6-monthly clinical 
reviews of the down-referred children at the tertiary referral hospital.[16] 
In contrast, the support available in our study was much less intensive, 
consisting of telephonic support for clinicians caring for HIV-infected 
children at the PHC clinics, and monthly clinical mentoring visits by 
an infectious diseases subspecialist from RCWMCH.
Another difference between our study and the Thai study is the 
age of the children. In the Thai study, the median age at initiation 
was 8.6 years, compared with 11 months for our cohort. In a study 
of >5 000 infants (<12 months of age) initiated on ART in southern 
Africa, the 3-year mortality and LTFU estimates were 16% and 29%, 
respectively.[13] These results suggest that HIV-infected infants are 
extremely vulnerable during the initial period on ART. More than 
50% of the down-referred children in our study were infants at ART 
initiation, and this may partly explain the high prevalence of LTFU. 
In the study from Dora Nginza Hospital, however, the median age 
at ART initiation was 4 years and the median age at transfer 8 years, 
suggesting that age alone is an insufficient explanation for the high 
prevalence of LTFU.
Death may have accounted for some of the children designated 
as LTFU in our study. In a study of the outcome of >3 000 HIV-
infected children treated with ART in four SA provinces, linkage to 
the national death registry confirmed mortality of 34% of 68 children 
with valid identity numbers.[17]
Another factor that may have contributed to LTFU in our study 
is the movement of patients between treating clinics and other parts 
of SA without the knowledge of the attending clinicians. While 
those who continued care in the Western Cape should have been 
identified through the search of the provincial database, the lack of 
a national unique patient identifier prohibits the tracing of patients 
who continue care in other provinces. In our study, within 12 months 
of down-referral, 1.7% of children had a documented transfer to 
another province. In the Dora Nginza hospital study, 18% of those 
who successfully transferred had a subsequent transfer to another 
facility during the study period. These figures show that many 
children receiving ART may experience multiple transfers between 
treatment facilities, with or without the knowledge of treating 
physicians.
The results of our study and the Dora Nginza Hospital study 
suggest that the process of transitioning care from one site to another 
is inherently vulnerable. However, evidence to guide down-referral 
criteria or to assist in identifying those children at high risk of 
LTFU is severely limited. Although clinical stability is reported as a 
down-referral criterion, those down-referred in this study included 
children recently initiated on ART, children with unsuppressed 
VLs, and children who had defaulted from ART while in care at 
the OHC. Documented viral suppression was not associated with 
increased retention in care. In the Dora Nginza study, 16% of 
transferred children had VLs >1 000 copies/mL. Importantly, in the 
study by Morsheimer et al.[10] 77% of patients down-referred with 
unsuppressed VLs achieved virological suppression within 6 months 
of treatment at the PHC clinic, suggesting improved adherence 
possibly resulting from reduced barriers to accessing care. This 
raises further doubt about the validity of ‘clinical stability’ as a down-
referral criterion.
Unfortunately, our study did not identify any specific factors 
associated with successful down-referral. Although the primary 
caregiver accessing a support grant and coexistent TB disease at 
the time of ART initiation were both associated with non-retention 
in care, neither was significant in multivariable models and it is 
difficult to understand the relevance of this finding. The Dora Nginza 
study also failed to identify risk factors for unsuccessful down-
referral, but in the study of adolescent transfer in the Western Cape, 
virological suppression was associated with successful transfer.[15] 
While documented VL suppression was not associated with retention 
in care in our study, it would be important to assess this in larger 
cohorts of similarly aged young children.
Until further evidence allows us to stratify risk of LTFU at 
down-referral, clinicians should regard this transition of care as a 
vulnerable point in the management of children living with HIV. 
Greater attention should be given to monitoring down-referred 
children and strengthening the support provided to them and their 
caregivers. While the level of support given to down-referred children 
in the Thai study[16] is perhaps unrealistic in the SA context, more 
formalised communications with referral sites and telephonic contact 
tracing of patients after down-referral is feasible. Furthermore, 
community adherence support has been shown to improve retention 
in care of children on ART in the SA public sector and should be 
considered for caregivers of children down-referred to community 
clinics on ART.[18]
Study strengths and limitations
This is one of the first SA studies that has followed a cohort of 
children receiving ART at a tertiary referral hospital through the 
process of down-referral to PHC clinics and evaluated their clinical 
responses during the first year after down-referral. It provides a 
unique perspective on the impact of the down-referral process 
on paediatric ART provision and care under routine operational 
conditions.
There are a number of limitations to this study. The main limita-
tion is the lack of a comparator group who were not down-referred, 
preventing comparison of outcomes between these two groups. 
The small cohort size may also have limited the ability to detect 
significant factors affecting retention in care. Furthermore, the study 
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only looked at two of the PHC clinics that fall into the RCWMCH 
drainage area, so the results are not necessarily generalisable. Finally, 
the study design did not allow for collection of data at PHC clinics 
other than the two designated referral clinics. Response to ART 
after down-referral therefore could not be assessed for those who 
continued care at other sites.
Conclusions
This study has shown that the greatest risk of LTFU and treatment 
interruption associated with down-referral in provision of paediatric 
ART occurs at the point of down-referral. Children who successfully 
navigate this transition in care show sustained clinical and virological 
improvements.
Acknowledgements. We are grateful to Dr Tony Hawkridge, Western Cape 
Department of Health, for permission to search the provincial electronic 
databases for ART data on a subset of patients and to Dr Nicki Tiffin and 
Prof. Andrew Boulle of the Western Cape Provincial Health Data Centre 
for assistance with the database searches.
Author contributions. JC drafted the study protocol, collected and analysed 
the data, and drafted the manuscript. PA assisted with extraction of data 
from the RCWMCH database and patient folders. M-AD contributed 
to the data extraction, data analysis and drafting of the manuscript. BE 
conceived the study and participated in the data analysis and drafting of 
the manuscript. All authors read and approved the final manuscript.
Funding. M-AD and BE receive funding from the National Institutes of 
Health for the International Epidemiologic Databases to Evaluate AIDS 
Southern Africa research collaboration (grant no. U01AI069924).
Conflicts of interest. None.
1. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected 
and uninfected infants born to HIV-infected mothers in Africa: A pooled analysis. Lancet 
2004;364(9441):1236-1243. https://doi.org/10.1016/S0140-6736(04)17140-7
2. Innes S, Lazarus E, Otwombe K, et al. Early severe HIV disease precedes early antiretroviral therapy 
in infants: Are we too late? J Int AIDS Soc 2014;17(1):18914. https://doi.org/10.7448/IAS.17.1.18914
3. UNAIDS. 2015 Progress report on the global plan towards the elimination of new HIV infections 
among children and keeping their mothers alive. 26 November 2015. http://www.unaids.org/en/
resources/documents/2015/JC2774_2015ProgressReport_GlobalPlan (accessed 20 February 2016).
4. National Department of Health. The South African Antiretroviral Treatment Guidelines 2013. http://
www.sahivsoc.org/Files/2013%20ART%20Treatment%20Guidelines%20Final%2025%20March%20
2013%20corrected.pdf (accessed 20 February 2016).
5. Zachariah R, Ford N, Philips M, et al. Task shifting in HIV/AIDS: Opportunities, challenges and 
proposed actions for sub-Saharan Africa. Trans R Soc Trop Med Hyg 2009;103(6):549-558. https://doi.
org/10.1016/j.trstmh.2008.09.019
6. Kredo T, Ford N, Adeniyi FB, Garner P. Decentralising HIV treatment in lower- and middle-income 
countries (Review). Cochrane Database Syst Rev 2013, Issue 6. Art. No.: CD009987. https://doi.
org/10.1002/14651858.CD009987.pub2
7. Eley B, Nuttall J. Antiretroviral therapy for children: Challenges and opportunities. Ann Trop Paediatr 
Int Child Health 2007;27(1):1-10. https://doi.org/10.1179/146532807X170448
8. Johnson L. Children count – children starting ART. http://www.childrencount.ci.org.za/indicator.
php?id=5&indicator=20 (accessed 11 July 2012).
9. Davies MA, Tsondai P, Tiffen N, et al. Where do HIV-infected adolescents go after transfer? Tracking 
transition/transfer of HIV-infected adolescents using linkage of cohort data to the health information 
system platform. J Int AIDS Soc 2017;20(Suppl 3):16-24. https://doi.org/10.7448/IAS.20.4.21668 
10. Morsheimer MM, Dramowski A, Rabie H, Cotton MF. Paediatric ART outcomes in a decentralised 
model of care in Cape Town, South Africa. South Afr J HIV Med 201415(4):148-153. https://doi.
org/10.4102/sajhivmed.v15i4.332
11. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data 
2000;314(314):1-27.
12. World Health Organization. WHO Case Definitions of HIV for Surveillance and Revised Clinical 
Staging and Immunological Classification of HIV-Related Disease in Adults and Children. Geneva: 
WHO, 2007. http://www.who.int/hiv/pub/guidelines/hivstaging/en/ (accessed 22 February 2016).
13. Technau K-G, Schomaker M, Kuhn L, et al. Virologic response in children treated with abacavir-
compared with stavudine-based antiretroviral treatment: A South African multi-cohort analysis. 
Pediatr Infect Dis J 2014;33(6):617-622. https://doi.org/10.1097/INF.0000000000000222
14. Porter M, Davies M, Mupani MK, et al. Outcomes of infants starting antiretroviral therapy in southern 
Africa, 2004-2012. J Acquir Immune Defic Syndr 2015;69(5):593-601 https://doi.org/10.1097/
qai.0000000000000683
15. Teasdale CA, Sogaula N, Yuengling KA, et al. High risk of loss to follow-up among South African 
children on ART during transfer, a retrospective cohort analysis with community tracing. J Int AIDS 
Soc 2017;20(1):21748. https://doi.org/10.7448/IAS.20.1.21748
16. Hansudewechakul R, Naiwatanakul T, Katana A, et al. Successful clinical outcomes following 
decentralization of tertiary paediatric HIV care to a community-based paediatric antiretroviral 
treatment network, Chiangrai, Thailand, 2002 to 2008. J Int AIDS Soc 2012;15(2):17358. https://doi.
org/10.7448/IAS.15.2.17358
17. Fatti G, Bock P, Eley B, Mothibi E, Grimwood A. Temporal trends in baseline characteristics and 
treatment outcomes of children starting antiretroviral treatment: An analysis in four provinces in 
South Africa, 2004 - 2009. J Acquir Immune Defic Syndr 2011;58(3):e60-e67. https://doi.org/10.1097/
QAI.0b013e3182303c7e
18. Grimwood A, Fatti G, Mothibi E, Malahlela M, Shea J, Eley B. Community adherence support 
improves programme retention in children on antiretroviral treatment: A multicentre cohort study in 
South Africa. J Int AIDS Soc 2012;15(2):17381. https://doi.org/10.7448/IAS.15.2.17381
Accepted 8 November 2017.
